Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

106.37 +1.33 (+1.27%)
Streaming Delayed Price Updated: 11:45 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,381,269
Open 105.36
Bid (Size) 106.36 (300)
Ask (Size) 106.38 (100)
Prev. Close 105.04
Today's Range 105.28 - 106.64
52wk Range 73.31 - 105.84
Shares Outstanding 2,531,374,696
Dividend Yield 3.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based... 
Via PredictStreet
Topics Initial Public Offering
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property

Performance

YTD
+7.3%
+7.3%
1 Month
+5.9%
+5.9%
3 Month
+33.0%
+33.0%
6 Month
+32.4%
+32.4%
1 Year
+7.0%
+7.0%

More News

Read More
News headline image
Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition
Via PredictStreet
Topics Economy
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
Via MarketMinute
Topics Intellectual Property
News headline image
Top 5 US Healthcare Stocks By Market Value ↗
Via Stocktwits
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
Via MarketMinute
Topics Economy
News headline image
SCHD vs. NOBL: Different Paths to Dividend Stability ↗
Via The Motley Fool
Topics ETFs
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
Better Buy in 2026: Pfizer or Merck? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
Via Stocktwits
Topics Government World Trade
News headline image
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck & Co. Inc. (NYSE:MRK) Stands Out as a Durable Dividend Stock ↗
Via Chartmill
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
Via Stocktwits
Topics Economy Government
News headline image
This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Merck Scores FDA Fast-Track Review For Key Cholesterol And Cancer Drugs With Multibillion-Dollar Potential: Report ↗
Via Stocktwits
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
Via Stocktwits
Topics Government World Trade
News headline image
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast ↗
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
Via MarketMinute
Topics Intellectual Property
News headline image
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? ↗
Via The Motley Fool
Topics Bonds Economy Intellectual Property

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 106.37
When was Merck & Co last traded?
The last trade of Merck & Co was at 12/24/25 11:45 AM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 269.26B
How many shares of Merck & Co are outstanding?
Merck & Co has 269B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.